![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_130,h_50,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
![DISRUPTLogo-MedHorizontal[1].png](https://static.wixstatic.com/media/1ad237_0694e719fff24e1b99901c9a23a001c1~mv2.png/v1/fill/w_500,h_200,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/DISRUPTLogo-MedHorizontal%5B1%5D.png)
Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies
In this Phase 1/2 study, researchers are investigating BT7480, a potential treatment, in patients who have advanced malignancies associated with Nectin-4. They aim to understand how safe the treatment is, how it moves through the body, and its initial effectiveness in treating these types of cancers.
Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works |
For more information about the trial, click the link below:
Clinical Trial Site: Columbia
To see all available clinical trials click here.
Yorumlar